Jennifer has over 20 years of experience as an oncologist specializing in early drug development in academia and industry - as an Associate Professor at MD Anderson Cancer Center, a Clinical Program Leader at The Novartis Institutes for BioMedical Research (NIBR) and a Chief Medical Officer in small biotech. At MD Anderson she was the Principal Investigator on over 30 Phase 1/2 trials and co-author of 145 peer-reviewed publications. In industry, Jennifer has built and led teams to early milestones including anti-PD-L1 antibody FAZ053, the first Novartis immunotherapy compound to achieve clinical proof-of-concept in dose escalation, HER2-TLR7/8 immune stimulatory antibody conjugate NJH395 (Novartis), and bifunctional EGFR/TGFb Trap fusion protein BCA101 (Bicara Therapeutics).

Jennifer completed a breast medical oncology fellowship at Memorial Sloan Kettering, a medical oncology fellowship at Yale Cancer Center and an internal medicine residency at Columbia University / NewYork-Presbyterian Hospital. She earned an M.D. from Cornell Medical College and an A.B. in Art History from Princeton University.

She is the Founder of Collage, a nonprofit that provides personalized art programs for patients living with cancer.

Ms. Devenyns has over 25 years of experience in the financial industry in both investment banking and venture capital in the healthcare sector. Prior to joining Precirix as CEO in 2017, she was CFO of Ogeda, a Belgium-based clinical-stage drug discovery company, until their acquisition by Astellas Pharma Inc. Ms. Devenyns has a master’s in applied economics from the University of Ghent.

Jasper Bos, PhD is a former Merck executive and is currently General Partner at Forbion working on the firm’s Growth Fund. Before joining the Dutch company in its Naarden-based headquarters, Jasper was Senior Vice President and Managing Director at M Ventures, the venture arm of pharmaceutical giant Merck. At M Ventures, he led a team of 21 investment professionals with a fund size of EUR 400m invested in over 50 companies spanning biotech, life sciences tools, and tech companies ranging from seed-stage to cross-over and IPO. He has experience in several operational roles for portfolio companies, and played a key role in the creation of multiple successful Merck spin-out companies . Jasper holds a PhD in Pharmacy from the University of Groningen, the Netherlands.

Simone Botti is a Partner in the Healthcare team at INKEF. Simone brings more than 15 years of experience across venture capital, start-up creation and leadership. Before joining INKEF, Simone was CEO of Metabomed, an early-stage cancer metabolism company he co-founded while he was Head of the Israel Bioincubator Fund at M Ventures. Simone built his company-building experience while at M Ventures, where he established a number of early-stage companies. During that time Simone also served as a Board Member of IATI, the Israel Advanced Technology Industries association. Previously, he was Vice President Business Development at RAD Biomed Accelerator, one of Israel’s leading life science incubators. Simone did his PhD in Structural Biology and Neurobiology at the Weizmann Institute of Science, where he received the “Dov Elad” prize in Structural Biology.

Sabine Dandiguian is Managing Partner at Jeito Capital and has over 30 years of experience in the pharmaceutical and medical devices industry. She has in-depth operational and strategic capabilities, particularly in market access, innovative “business models” and management. Prior to Jeito, she spent 20 years at Johnson & Johnson, in operational positions of increasing responsibility in the pharmaceutical sector (Janssen) and medical devices. Her last position has been Company Group Chairman, President Europe of Johnson & Johnson’s medical. Sabine has been recognized as Chevalier de l’Ordre du Mérite, Chevalier de la Légion d’Honneur and is a member of the « Assemblée des 100 » of Institut Pasteur. She has been a member of W.I.T.H. (Women Innovating Together in Healthcare) since its creation. Sabine graduated in Finance from ESCP Business School (Grande Ecole).

Morten Graugaard Døssing joined Novo Holdings in 2016 and serves as Partner in the company creation team of Novo Seeds where he leads new company formation. He currently serves on the Board of Acesion Pharma, Avilex Pharma, Hoba Therapeutics, NMD Pharma, Stipe Therapeutics, and Syndesi Therapeutics.

Previously, he was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new biotech companies. Earlier in his career, he co-led the life science consulting practice at a Copenhagen-based boutique advisory firm focusing on business development and management consulting. Morten holds an MSc in human biology from the University of Copenhagen.

Thomas Ramdahl is a pharmaceutical executive with more than 20 years of clinical and development experience. In 2001, he became President and first CEO of Algeta ASA, a Norwegian biotech company that successfully developed and launched a radiopharmaceutical for prostate cancer. Furthermore, he was instrumental in Algeta’s 2007 IPO, as well as in the acquisition of the company by Bayer AG for USD 2.9B in 2014. Dr. Ramdahl has authored more than 40 publications and is a co-inventor of several patents. He gained his PhD in environmental chemistry from the University of Oslo in 1984 and an MSc in organic chemistry from the Norwegian Institute of Technology in 1979. He has also been engaged in executive training at the International Institute for Management Development (IMD) in Lausanne, Switzerland.

Mårten Steen is Managing Partner at HealthCap. Prior to re-joining HealthCap in 2010, Dr. Steen worked with global business development at Merck Serono as a Director, focusing on both product and technology licensing. Prior to Merck Serono, he was a medical associate with HealthCap. Dr. Steen is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003. He is the author of 16 scientific papers published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.

Michaël Vlemmix has a background in healthcare and investment banking. Prior to joining Gimv in 2017, he was an equity analyst at KBC Securities focusing on the healthcare sector. He started his professional career at a medical device spin-off of the University of Antwerp where he also obtained a master’s degrees in bio-engineering (biotechnology) and management.